At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,355 enrolled
Drug / intervention
Pitavastatindrug
Likely dose
Pitavastatin 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label, Long-Term (1 Year) Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
In Brief
A Phase 3 clinical trial evaluating Pitavastatin for Hypercholesterolemia and Dyslipidemia. Completed, enrolled 1,355 participants across 186 sites in 13 countries.
Detailed Summary
This study is a long-term follow-up protocol for patients who participated in study NK-104-3.01EU or study NK-104-3.02EU.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia, Dyslipidemia
CountriesDenmark, Finland, Germany, India, Israel, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2006
Enrollment StartJul 2006
Primary CompletionNov 2007
TodayJul 2026
First PostedMay 15, 2006
Enrollment StartJul 1, 2006
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.1 years ago
Interventions
Pitavastatindrug
Pitavastatin 4 mg once daily